TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14633532

Group type: EXPERIMENTAL
Intervention: Triple preincisional analgesic therapy (rofecoxib 50 mg PO, 0.25% bupivacaine/0.5% lidocaine field block, ketamine 0.2 mg/kg IV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo PO before surgery
Number of subjects: 34
Study: 10923937

Group type: EXPERIMENTAL
Intervention: Internal thermistors
Number of subjects: 6
Study: 9414355

Group type: EXPERIMENTAL
Intervention: Enhanced sign incorporating human factor principles (colour, signal word panel, icons/pictorial, explicit wording)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original sign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two other signs (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-sign period (control)
Number of subjects: 0
Study: 1347763

Group type: EXPERIMENTAL
Intervention: 100 mg xamoterol twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg xamoterol twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Xamoterol (100 mg and 200 mg)
Number of subjects: 12
Study: 3896701

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 30208475

Group type: EXPERIMENTAL
Intervention: aP vaccine plus HBV (n = 221)
Number of subjects: 440

Group type: COMPARATOR
Intervention: HBV only (control group; n = 219)
Number of subjects: 440
Study: 30444092

Group type: EXPERIMENTAL
Intervention: Programmed irrigation aspiration sanation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 128
Study: 24442160

Group type: EXPERIMENTAL
Intervention: First-reader computer-aided detection (CAD) followed by fast 2-dimensional review (DR FR-CAD)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Second-reader CAD (SR CAD)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Unassisted reading
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Double reading with first-reader CAD
Number of subjects: 182
Study: 22370444

Group type: EXPERIMENTAL
Intervention: 3 g WBE/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 10 g WBE/d
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0 g WBE/d (placebo)
Number of subjects: 63
Study: 19920806

Group type: EXPERIMENTAL
Intervention: NCX-1000
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18540008

Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Bovine-derived Sigma hyaluronidase
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mixed transfers
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Transfers of only embryos from rHuPH20 treatment
Number of subjects: 135

Group type: COMPARATOR
Intervention: Transfers of only embryos from bovine hyaluronidase treatment
Number of subjects: 135
Study: 15935238

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 201

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Continuing mood stabilizer therapy
Number of subjects: 201
Study: 14583180

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 6

Group type: COMPARATOR
Intervention: Group E (diabetes patients with ASO undergoing hemodialysis)
Number of subjects: 6
Study: 10319523

Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Education Program (CHEP)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study: 8740607

Group type: EXPERIMENTAL
Intervention: Amitriptyline (dose escalated from 25 mg to 100 mg per day over 4 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1721814

Group type: EXPERIMENTAL
Intervention: 10% HES 200/0.5 + Naftidrofuryl
Number of subjects: 2

Group type: COMPARATOR
Intervention: 6% HES 200/0.5 + Naftidrofuryl
Number of subjects: 2
Study: 7046784

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole by intramuscular injection immediately before operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibacterial cover (Control)
Number of subjects: 100
Study: 31177635

Group type: EXPERIMENTAL
Intervention: Theatre Improvisation Training to Promote Social Cognition (TIPS) - 18 weekly 2-hour group sessions led by a theatre director and actor-assistant.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CR controls who were not enrolled in the study but completed follow-up assessments using the same methods).
Number of subjects: 36
Study: 31523988

Group type: EXPERIMENTAL
Intervention: Community-Based Primary Care Project (intervention group)
Number of subjects: 30460

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30460
Study: 27855297

Group type: EXPERIMENTAL
Intervention: Nurse-led dementia education and knowledge translation programme
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study: 25050468

Group type: EXPERIMENTAL
Intervention: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC) administered intradermally at a weekly interval for 4 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC)
Number of subjects: 7
Study: 23388087

Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treadmill training without virtual reality (active control)
Number of subjects: 300
Study: 21114605

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 19236376

Group type: EXPERIMENTAL
Intervention: Sequential deferiprone-deferoxamine (DFO-DFP)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Deferiprone (DFP) alone
Number of subjects: 213
Study: 17599426

Group type: COMPARATOR
Intervention: Simvastatin (titrated to 40 mg/day if necessary) plus placebo
Number of subjects: 5518

Group type: EXPERIMENTAL
Intervention: Simvastatin (titrated to 40 mg/day if necessary) plus active fenofibrate 160 mg/day (or 54 mg/day if eGFR 30 to <50 mL/min per 1.73 m2)
Number of subjects: 5518
Study: 15533894

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (25,000, 50,000, or 75,000 IU daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11826728

Group type: EXPERIMENTAL
Intervention: Simulated finger disability (loss of four fingers in the preferred hand and the thumb in the nonpreferred hand)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physical restraint (torso restrained or unrestrained)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Type of control and height of control location
Number of subjects: 10
Study: 9802965

Group type: EXPERIMENTAL
Intervention: 6 mg nebulized glyceryl trinitrate (GTN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study: 7916551

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (blood withdrawn before muscle relaxants)
Number of subjects: 40
Study: 2681580

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline (IURT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard interventions (Control)
Number of subjects: 50
Study: 4469041

Group type: EXPERIMENTAL
Intervention: Norethandrolone (Nilevar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-thyroxine (Choloxin)
Number of subjects: 0
Study: 30742386

Group type: EXPERIMENTAL
Intervention: Combined effect of magnetolaser therapy (MLT) and red light (10 procedures per course)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic therapeutic complex (medicamentous therapy, prostate massage, diet therapy, therapeutic gymnastics)
Number of subjects: 120
Study: 26279411

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN) 0.4 mg/h
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maternal arterial blood pressure
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MCA-PI
Number of subjects: 35
Study: 24912462

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR, 12 sessions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with venlafaxine XR
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (European Americans receiving combined treatment)
Number of subjects: 42
Study: 23214249

Group type: COMPARATOR
Intervention: Walsh or Poor method for handling the dorsal venous complex (DVC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Three additional hemostatic procedures including prophylactic suture, ligation of vascular bundle, and absorbable sutures
Number of subjects: 100
Study: 20212016

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet (HC)
Number of subjects: 76
Study: 18402097

Group type: EXPERIMENTAL
Intervention: Light-cured calcium hydroxide (Ca(OH)2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diluted formocresol (FC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiographic scoring
Number of subjects: 20
Study: 15811138

Group type: EXPERIMENTAL
Intervention: High protein diet (25 E% protein, 45 E% carbohydrate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (58 E% carbohydrate, 12 E% protein)
Number of subjects: 50
Study: 11759109

Group type: EXPERIMENTAL
Intervention: IFN + ribavirin
Number of subjects: 55

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 55
Study: 9140633

Group type: EXPERIMENTAL
Intervention: New atypical antipsychotic
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline examination
Number of subjects: 23
Study: 7951124

Group type: EXPERIMENTAL
Intervention: MTX (Methotrexate) for low risk of GVHD
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: MTX + CsA (Cyclosporine A) for high risk of GVHD
Number of subjects: 73

Group type: COMPARATOR
Intervention: Retrospective controls (MTX + CsA for 1 year)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: BuCY conditioning
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CY/TBI conditioning
Number of subjects: 73

Group type: COMPARATOR
Intervention: Retrospective controls
Number of subjects: 73
Study: 3300133

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg orally 1 hour before abortion and again 4 and 8 hours after
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 118
Study: 2568793

Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 72

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 72
Study: 31987237

Group type: EXPERIMENTAL
Intervention: Traditional Thai Massage (TTM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Thai Massage with Herbal Compress (TMH)
Number of subjects: 140
Study: 31627728

Group type: EXPERIMENTAL
Intervention: 30 ml of 0.4% ropivacaine (Group T)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 104
Study: 28902593

Group type: EXPERIMENTAL
Intervention: PFO closure plus long-term antiplatelet therapy
Number of subjects: 663

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: PFO closure, oral anticoagulation, and antiplatelet therapy
Number of subjects: 663
Study: 25395283

Group type: EXPERIMENTAL
Intervention: Figitumumab (20 mg/kg) plus erlotinib (150 mg/day)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 579
Study: 23886531

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) and thoracic periaortic adipose tissue (TAT) volumes measured by computed tomography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perivascular fat depots (EAT and TAT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perivascular fat
Number of subjects: 100
Study: 22236538

Group type: EXPERIMENTAL
Intervention: LC-IOES
Number of subjects: 226

Group type: COMPARATOR
Intervention: LC-LCBDE
Number of subjects: 226
Study: 19820793

Group type: EXPERIMENTAL
Intervention: CustomCornea
Number of subjects: 50

Group type: COMPARATOR
Intervention: Zyoptix
Number of subjects: 50
Study: 16755855

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prestarium
Number of subjects: 36
Study: 15004870

Group type: EXPERIMENTAL
Intervention: Behavior modification (60-70 minutes, once a week for 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no management or treatment)
Number of subjects: 62
Study: 11520714

Group type: EXPERIMENTAL
Intervention: Terbutaline inhalation via a pressurized metered-dose inhaler
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Terbutaline inhalation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: sRaw bronchodilator response
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 9764456

Group type: EXPERIMENTAL
Intervention: Ticlopidine, 250 mg b.d. for 7 days before surgery and continued for 28 days after surgery
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 8154176

Group type: EXPERIMENTAL
Intervention: 300 mg ASA daily
Number of subjects: 223

Group type: COMPARATOR
Intervention: 1000 mg ASA daily
Number of subjects: 223
Study: 3230904

Group type: EXPERIMENTAL
Intervention: Flexibility before
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flexibility after
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flexibility before and after
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 48
Study: 31701133

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.25 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31694699

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy-based program designed to enhance resilience, focusing on emotion regulation through cognitive reappraisal, delivered in four bi-weekly 120-min sessions.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group participating in a series of group discussions.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy-based program.
Number of subjects: 140
Study: 28651159

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study: 26354104

Group type: EXPERIMENTAL
Intervention: Lingual tonsillectomy (LT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Hyoid suspension type 2 (HS) + radiofrequency treatment of the base of the tongue (RFT TB)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Simultaneous tonsillectomy
Number of subjects: 108
Study: 23128427

Group type: EXPERIMENTAL
Intervention: Lower-intensity treadmill exercise (50 minutes at 40%-50% of heart rate reserve)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stretching and resistance exercises (2 sets of 10 repetitions on each leg on 3 resistance machines)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Higher-intensity treadmill exercise (30 minutes at 70%-80% of heart rate reserve)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lower-intensity treadmill exercise
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Higher-intensity treadmill exercise
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stretching and resistance exercises
Number of subjects: 67
Study: 21831718

Group type: EXPERIMENTAL
Intervention: Induction pemetrexed and cisplatin followed by maintenance pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab
Number of subjects: 0
Study: 19781209

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg b.i.d for 3 days before and after intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no probucol treatment)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg b.i.d
Number of subjects: 205
Study: 16388882

Group type: EXPERIMENTAL
Intervention: self-regulatory skills training focused on exercise planning strategies
Number of subjects: 198

Group type: COMPARATOR
Intervention: standard-care control group
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: self-regulatory skills training
Number of subjects: 198
Study: 14513873

Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11751733

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9431834

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 0
Study: 8516658

Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg/day
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: COMPARATOR
Intervention: Metoclopramide 30 mg/day
Number of subjects: 147

Group type: COMPARATOR
Intervention: Domperidone 30 mg/day
Number of subjects: 147
Study: 3320783

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (with methyldopa or propranolol if necessary)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 785
Study: 29065271

Group type: EXPERIMENTAL
Intervention: STG graft
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ST4 graft
Number of subjects: 62
Study: 27880789

Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behavior Therapy (RFCBT) for 8 weeks
Number of subjects: 33
Study: 25097754

Group type: EXPERIMENTAL
Intervention: SUB‐B (10,000 AUN/ml)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Stal‐B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SUB‐B and Stal‐B
Number of subjects: 74
Study: 22634532

Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (RHES) for ten days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Negative control (no RHES)
Number of subjects: 15
Study: 19955506

Group type: EXPERIMENTAL
Intervention: Aminophylline 6 mg/kg IV, followed by 1.5 mg x kg(‐1) x h(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 17565524

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening test
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Visiting a doctor for a checkup
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Personal or family history of colon polyps or cancer
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Asking for a colorectal cancer screening test
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Financial concerns
Number of subjects: 1050
Study: 16525946

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17
Study: 12164999

Group type: EXPERIMENTAL
Intervention: Computerized version of the Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Computer experience
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Age, education, and cognitive function
Number of subjects: 43
Study: 10442940

Group type: EXPERIMENTAL
Intervention: Particulate dentin and plaster of paris combination
Number of subjects: 10
Study: 8559961

Group type: EXPERIMENTAL
Intervention: Physical activity sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Guidance in nutrition and behavior modification
Number of subjects: 42
Study: 2151369

Group type: EXPERIMENTAL
Intervention: Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate (TAM/HD‐MPA)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Continuous tamoxifen (TAM)
Number of subjects: 170
Study: 883328

Group type: EXPERIMENTAL
Intervention: Wide local excision
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard radical mastectomy
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Both treatments (wide local excision and radical mastectomy)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Stage II cancer patients
Number of subjects: 370
Study: 31987546

Group type: EXPERIMENTAL
Intervention: Straight-line group (SLG) - 1 × 15 repetitions of 20-meter sprints in line
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Change-of-direction group (CODG) - 1 × 15 repetitions of 20-meter sprints with two changes in each repetition
Number of subjects: 26
Study: 30744113

Group type: EXPERIMENTAL
Intervention: High-cholesterol meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-cholesterol meal
Number of subjects: 0
Study: 26954588

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral intervention (7 sessions)
Number of subjects: 105
Study: 26906139

Group type: EXPERIMENTAL
Intervention: Art group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diversional music group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 24665014

Group type: EXPERIMENTAL
Intervention: Nintendo Wii balance board training for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual sports activities (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unilateral stance tests (both groups)
Number of subjects: 20
Study: 22538676

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic colectomy (SILC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic colectomy (CLC)
Number of subjects: 50
Study: 20164333

Group type: EXPERIMENTAL
Intervention: Activation of anterior VMPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activation of posterior VMPFC
Number of subjects: 0